AstraZeneca said Friday that its recently approved breast cancer drug Etcamah failed a late-stage trial designed to support a ...
FDA approves Scholar Rock's Isembyld (apitegromab) for SMA after Indiana manufacturing hurdles; shares jump 10% premarket.
Definium Therapeutics' DT120 met endpoints in Phase 3 Panorama GAD trial, planning FDA submission for DT120 in GAD and MDD ...
As gene therapy manufacturing continues to mature, the focus is shifting. Most gene therapy developers begin this work ...
Akeso/Summit's ivonescimab cut death risk 27% vs Merck's Keytruda in HARMONi-2 lung cancer trial; median survival 30.75 vs 22 ...
Welcome back to another edition of Endpoints Weekly! While it is still technically summer, the season is starting to turn now ...
Alzheon, a biotech that has been attempting to treat Alzheimer's with a checkered drug candidate for more than a decade, is ...
Andy Plump's upcoming retirement marks another major change to Takeda's leadership team after Christophe Weber handed the keys to Julie Kim.
Yarrow Bioscience raises $150M; AbbVie's Qulipta succeeds in Phase 3 menstrual migraine trial; Sino Biopharm pays $668M for 5 ...
Anthropic posts a corporate development role for life sciences dealmaking, paying up to $600,000, as its biotech push and IPO ...
TwoStep raised a $62.5M Series A backed by Pfizer and Merck KGaA's venture arms to push its peptide-drug conjugate toward Phase 1 this year.
Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results